Systemic biomarkers of treatment response to methotrexate in people with painful knee osteoarthritis: A biological substudy of the PROMOTE randomised controlled clinical trial
Osteoarthritis and Cartilage · 2026-10 · 34 (10) · 1539-1549
DOI: 10.1016/j.joca.2026.07.002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Osteoarthritis and Cartilage, 2026-10. Verfasst von Jiahao Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Inflammation, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Osteoarthritis, Knee, Methotrexate, Antirheumatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Arthritis UK, UK Research and Innovation, Leeds Biomedical Research Centre.
Abstract (Originalsprache)
OBJECTIVE: Stratification of therapeutic responses may help identify efficacious therapies for osteoarthritis (OA). In the PROMOTE randomised trial, participants with elevated baseline high-sensitivity C-reactive protein (hs-CRP) showed greater pain reduction after methotrexate treatment. We set out to interrogate a broader panel of serum/plasma inflammatory response markers relevant to methotrexate actions as potential biomarkers of therapeutic effect. Our objectives were to: (i) characterize changes in these systemic markers during methotrexate treatment; determine whether (ii) baseline levels or (iii) changes in any marker during treatment were associated with treatment response; and (iv) compare these findings with the more established clinical inflammatory marker, hs-CRP. DESIGN: Plasma/serum samples from participants in PROMOTE's biological substudy were analysed for 35 inflammatory markers at baseline (pre-treatment) and at 6-months (post-treatment), by MesoScale V-plex multiplex assay. Those with paired biological and clinical data at both baseline and 6-months were included in the substudy analysis set. Relationships between markers and overall data structure were assessed by Pearson correlation and Principal Component analysis. Associations between markers (baseline levels or change over time) and change in average knee pain severity in past week (numerical rating scale, NRS) were evaluated by univariable linear regression, adjusting for baseline age, sex, and body mass index. Least Absolute Shrinkage and Selection Operator (LASSO) regression with bootstrap resampling enabled marker selection. Benjamini-Hochberg correction adjusted for multiple testing (Padj). RESULTS: 87 participants with paired blood marker and clinical data were eligible for substudy analysis. 18/35 markers were quantifiable and analysed. Systemic IL-8 and TNF-α levels decreased (Padj=0.015, 0.048 respectively) while IL-15 increased (Padj=0.033) with methotrexate treatment over 6-months. Analysing within this active treatment randomised arm, higher baseline IFN-γ was associated with greater reduction in NRS pain change (0.66 [0.01, 1.31], P=0.047), as was decreasing TNF-α over 6-months (2.25 [0.00, 4.5], P=0.049). LASSO identified higher IFN-γ, lower plasma IL-15 and IL-16, and younger age as the most important baseline predictors of pain improvement. hs-CRP was highly selected by LASSO for treatment response in both arms. In a secondary univariate treatment arm-by-biomarker interaction analysis, of the 19 markers, only hs-CRP showed consistent effects in adjusted models (at baseline, coeffic. 2.34 [0.53, 4.15], P=0.001; change over 6-months, (0.36 [0.06, 0.66], P=0.018). CONCLUSIONS: Blood measurement of IFN-γ, TNF-α, IL-15 and IL-16 as well as hs-CRP could act as potential markers to stratify the treatment response by average knee pain to methotrexate in knee osteoarthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Inflammation, Imperial College London, London, UK.
- Arthritis UK Centre for Osteoarthritis Pathogenesis, Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, UK.
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK.
- Department of Immunology and Inflammation, Imperial College London, London, UK; Arthritis UK Centre for Osteoarthritis Pathogenesis, Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, UK. Electroni…
Förderung
- Arthritis UK
- UK Research and Innovation
- Leeds Biomedical Research Centre
Zitieren
APA
Liang, J., Papadaki, A., Alderson, J., Vincent, T. L., Conaghan, P. G., Kingsbury, S. R., & Watt, F. E. (2026). Systemic biomarkers of treatment response to methotrexate in people with painful knee osteoarthritis: A biological substudy of the PROMOTE randomised controlled clinical trial. Osteoarthritis and Cartilage, 34(10), 1539-1549. https://doi.org/10.1016/j.joca.2026.07.002
Vancouver
Liang J, Papadaki A, Alderson J, Vincent TL, Conaghan PG, Kingsbury SR, et al. Systemic biomarkers of treatment response to methotrexate in people with painful knee osteoarthritis: A biological substudy of the PROMOTE randomised controlled clinical trial. Osteoarthritis and Cartilage. 2026;34(10):1539-1549. doi:10.1016/j.joca.2026.07.002
BibTeX
@article{Liang2026,
author = {Liang, Jiahao and Papadaki, Artemis and Alderson, Jennifer and Vincent, Tonia L and Conaghan, Philip G and Kingsbury, Sarah R and Watt, Fiona E},
title = {Systemic biomarkers of treatment response to methotrexate in people with painful knee osteoarthritis: A biological substudy of the PROMOTE randomised controlled clinical trial},
journal = {Osteoarthritis and Cartilage},
year = {2026},
volume = {34},
number = {10},
pages = {1539--1549},
doi = {10.1016/j.joca.2026.07.002}
}
EUVIMED